Biotage AB (publ)

Biotage AB (publ), established in 1969 and based in Uppsala, Sweden, specializes in providing advanced separation technologies essential for fields such as organic and analytical chemistry, biomolecule research, and industrial scale-up applications. The company offers a comprehensive range of products, including solutions for organic and peptide synthesis, flash chromatography, evaporation, and work-up procedures, along with specialized systems, accessories, and various cartridges (normal, reversed, and specialty phase). Biotage also supplies solutions for plasmid and protein purification, encompassing antibody and tagged protein purification, automation systems, custom packing services, and diverse PhyTip columns. Additionally, they provide extensive sample preparation solutions tailored for clinical, bioanalytical, forensic, toxicology, doping control, environmental, and food and agriculture sectors, complemented by necessary consumables. Their offerings further include metal scavengers, reagents, and essential spare parts. Biotage serves a broad client base, including pharmaceutical and biotechnical companies, contract research and manufacturing organizations, government agencies, academic institutions, and various clinical, forensic, and academic laboratories. With a significant global footprint, the company operates in 70 countries across the Americas, Europe, the Middle East, Africa, and Asia Pacific.

Biotage AB (publ) trades as BIOT.ST on STO. The company is classified in Healthcare / Medical - Instruments & Supplies and reports in SEK.

The current profile places the business in Medical - Instruments & Supplies. This section is intended to summarize the operating segments, products, geographies, and main revenue lines from official filings.

Detailed operating-segment data is not available for this symbol yet.

Use this area for management strategy, capital allocation priorities, target markets, and measurable goals from the latest annual report or investor presentation.

The app now provides the structure, but exact strategic claims should come from official company documents before being treated as a finished investment thesis.

Biotage AB (publ) can be compared against peers such as AegirBio AB (publ), AroCell AB (publ), Bioservo Technologies AB (publ), Calliditas Therapeutics AB (publ), Elos Medtech AB (publ), InDex Pharmaceuticals Holding AB (publ).

A complete thesis should compare growth, margins, balance-sheet risk, valuation multiples, and market position against direct competitors.

Current signals to investigate include market capitalization of $11.46B, beta of 0.85, and return on equity of N/A.

This section should be validated with evidence such as durable margins, brand strength, regulation, switching costs, cost advantage, distribution, or technology.

Key risks should include financial leverage, cyclicality, customer concentration, regulatory exposure, currency risk, and execution risk.

BIOT.ST currently shows total debt of N/A and beta of 0.85. Missing data should be treated as a research gap, not as low risk.

Production-capacity detail is not available as structured data yet. For industrial, defense, semiconductor, or real-estate companies, this should be reviewed from annual reports and investor presentations.

No structured backlog field is available yet. If the company reports backlog, review the relevant filing section before adding it to the thesis.

Use this section for major contracts, product launches, construction projects, acquisitions, or strategic programs that can materially affect valuation.

No recent SEC-style filings are available for this symbol yet.

Customer concentration is not available as structured data here. Add it from official filings when a company discloses material customers or revenue concentration.

Supplier concentration and critical supply-chain dependencies are not available as structured data here. This should be researched from annual reports and risk disclosures.

Company website: https://www.biotage.com

For US-listed stocks, verify the thesis against official filings, earnings call transcripts, and company investor relations materials.